Acta Scientific Orthopaedics (ISSN: 2581-8635)

Short Communication Volume 5 Issue 4

Cancer Bone Metastasis, Diagnostic Insights and Drug Selection

Da-Yong Lu*, Bin Xu and Jin-Yu Che

School of Life Sciences, Shanghai University, Shanghai, PRC

*Corresponding Author: Da-Yong Lu, School of Life Sciences, Shanghai University, Shanghai, PRC.

Received: January 24, 2022; Published: March 21, 2022

Abstract

Cancer bone metastasis was common clinical events to many human cancer, such as breast, prostate and lung cancer. It is a devastating event that is difficult to therapeutic targeting and benefiting. Several reasons are major factors and drawback for disease management and therapeutic cure. To promote clinical treatment outcomes of bone metastasis, high-quality diagnosis and drug selection is indispensable. This editorial discusses bone cancer metastasis diagnosis and relevant therapeutics in the clinic.

Keywords: Bone Cancer; Neoplasm Metastasis; Drug Treatment; Personalized Medicine; Cancer Diagnosis

References

  1. Lambert AW., et al. “Emerging biological principles of metastasis”. Cell 168 (2017): 670-691.
  2. Ahmad AS., et al. “Trends in the lifetime risk of developing cancer in Great Britain; Comparison of risk for those born from 1930-1960”. British Journal of Cancer 112 (2015): 943-947.
  3. Mehlen P and Puisieux A. “Metastasis; a question of life or death”. Nature Reviews Cancer 6 (2006): 449-458.
  4. Weidenfeld K and Barkan D. “EMT and stemness in tumor dormacy and outgrowth: Are they intertwined processes?” Frontiers in Oncology 8 (2018): 381.
  5. Lu DY and Xu B. “Bone metastasis treatment, major frontiers”. Acta Scientific Orthopaedics7 (2021): 1-2.
  6. Hakim BAA. “Benign bone tumors, an overview”. Acta Scientific Orthopaedics10 (2021): 1-2.
  7. Lu DY and Xu B. “Bone cancer and metastatic trials, drug treatment”. Acta Scientific Orthopaedics9 (2021): 31-33.
  8. Lu DY., et al. “Cancer Metastasis treatments”. Current Drug Therapy1 (2013): 24-29.
  9. Lu DY and Xu B. “Cancer bone metastasis, experimental study”. Acta Scientific Orthopaedics12 (2021): 1-3.
  10. He JB., et al. “Inhibitory effects of Rhaponticin on osteoclast formation and resorption by targeting RANKL-induced NFATc 1 and ROS activity”. Frontiers in Pharmacology 12 (2021): 645140.
  11. Bhadresha KP., et al. “A predictive biomarker panel for bone metastasis, liquid biopsy approach”. Journal of Bone Oncology 29 (2021): 100371.
  12. Barani M., et al. “Recent advances in nanotechnology-based diagnosis and treatments of human osteosarcoma”. Biosensors 11 (2021): 55.
  13. Chen P., et al. “Detection of metastatic tumor cells in the bone marrow aspirate smears by artificial intelligence (AI)-based morphogo system”. Frontiers in Oncology 11 (2021): 742395.
  14. Jelgersma C and Vajkoczy P. “How to target spinal metastasis in experimental research: An overview of currently used experimental mouse model and future prospects”. International Journal of Molecular Sciences 11 (2021): 5420.
  15. Pantano F., et al. “Integrin alpha 5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions”. Oncogene 40 (2021): 1284-1299.
  16. Lu DY and Che JY. “Bone disease treatments, importance of technical supports”. Acta Scientific Orthopaedics4 (2021): 55-57.
  17. Lu DY., et al. “Anti-metastatic drug development, work out towards new direction”. Medicinal Chemistry7 (2018): 512 (192-196).
  18. Lu DY., et al. “Antimetastatic activities and mechanisms of bisdioxopiperazine compounds”. Anti-Cancer Agent Medicinal Chemistry7 (2010): 564-570.
  19. Zhu H., et al. “DJ-1 mediates the resistance of cancer cells to dihydroarteminisinin through cancer cells through reactive oxygen species removal”. Free Radical Biology and Medicine 71 (2014): 121-132.
  20. Lu DY., et al. “Development of antimetastatic drugs by targeting tumor sialic acids”. Scientia Pharmaceutica3 (2012): 497-508.
  21. Agarwal N., et al. “Natural herbs as anticancer drugs”. International Journal of PharmTech Research 3 (2012): 1142-1153.
  22. Lu DY., et al. “Natural drug cancer treatment strategies from herbal medicine to chemical or biological drug”. Studies in Natural Products Chemistry 66 (2020): 91-115.
  23. Lu DY and Lu TR. “Herbal medicine in new era”. Hospice Palliative Medicine International Journal4 (2019): 125-130.
  24. Lu DY., et al. “Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination-an effective strategy to improve clinical treatment”. Medical Hypotheses1 (2006): 45-51.
  25. Lu DY. “Personalized cancer chemotherapy, an effective way for enhancing outcomes in clinics”. Woodhead Publishing, Elsevier, UK (2014).
  26. Lu DY., et al. “Anticancer drug sensitivity testing, a historical review and future perspectives”. Current Drug Therapy1 (2015): 44-55.
  27. Volm M and Efferth T. “Prediction of cancer drug resistance and implications for personalized medicine”. Frontiers in Oncology (2015): 282.
  28. Lu DY and Lu TR. “Drug sensitivity testing, a unique drug selection strategy”. Advances in Biomarker Sciences and Technology 2 (2020): 59-66.
  29. Popova AA and Levkin PA. “Precision medicine in oncology: In vitro drug sensitivity and resistance test (DSRT) for selection of personalized anticancer therapy”. Advances in Therapeutics (2020): 1900100.
  30. Lu DY., et al. “Cancer bioinformatics for update anticancer drug developments and personalized therapeutics”. Reviews on Recent Clinical Trials2 (2016): 101-110.
  31. Lu DY., et al. “Pharmacogenetics of cancer therapy: breakthroughs from beyond?” Future Science OA 4 (2015): FSO.15, 80.
  32. Hyman DH., et al. “Implementing genome-driven oncology”. Cell 168 (2017): 584-599.
  33. Lu DY., et al. “Individualized cancer therapy, future approaches”. Current Pharmacogenomics and Personalized Medicine 2 (2018): 156-163
  34. Lu DY., et al. “Anticancer drug combinations, studies for all possibilities”. Advances in Pharmacoepidemiology and Drug Safety1 (2016): e138.
  35. Lu DY., et al. “Anticancer drug combination, how far we can go through?” Anti-Cancer Agents in Medicinal Chemistry 1 (2017): 21-28.
  36. Lu DY., et al. “Drug combination in clinical cancer treatment”. Reviews on Recent Clinical Trials3 (2017): 202-211.

Citation

Citation: Da-Yong Lu., et al. “Cancer Bone Metastasis, Diagnostic Insights and Drug Selection".Acta Scientific Orthopaedics 5.4 (2022): 90-92.

Copyright

Copyright: © 2022 Da-Yong Lu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US